

17 March 2021

Intuitive Investments Group plc

Investment in Polarean Imaging plc

Intuitive Investments Group plc (AIM: IIG) ("IIG" or the "Company"), a closed-end investment company focussed on the life sciences sector, announces an investment of £250,000 to acquire 416,666 ordinary shares of Polarean Imaging plc (AIM: POLX) ("Polarean") at a price of 60 pence per share (the "Investment"). The Investment is part of Polarean's fundraising as announced by Polarean on 15 March 2021 (the "Fundraising"). The Investment is conditional upon, amongst other things, each of the resolutions being passed at Polarean's forthcoming general meeting on 6 April 2021.

Polarean and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high-resolution medical imaging market. The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

Robert Naylor has personally invested £125,000 as part of the Fundraising. Accordingly, Robert Naylor did not vote as a member of the Board IIG approving the Investment.

For further information, please contact:

Intuitive Investments Group plcwww.iigplc.comDavid EvansVia Walbrook PRRobert Naylor

Strand Hanson Limited - Nominated Adviser +44 (0) 20 7409 3494
James Harris / James Dance / James Bellman +44 (0) 20 3657 0050

Turner Pope Investments (TPI) Ltd - Broker Andrew Thacker / Zoe Alexander

Walbrook PR Limited - Media & Investor Relations +44 (0)20 7933 8780 or intuitive@walbrookpr.com

+44 (0) 7980 541 893/+44(0)7748 651727

About Intuitive Investments Group plc

Paul McManus/Sam Allen

The Company is a newly established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman, David Evans, to seek to generate capital growth over the long term for shareholders.